IMU Stock Overview
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia.
Imugene Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.18|
|52 Week High||AU$0.54|
|52 Week Low||AU$0.13|
|1 Month Change||-2.63%|
|3 Month Change||-17.78%|
|1 Year Change||-63.73%|
|3 Year Change||516.67%|
|5 Year Change||1,056.32%|
|Change since IPO||89.74%|
Recent News & Updates
Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little MoreNov 11
Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth PlansAug 22
Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn SituationFeb 28
A Look At Imugene's (ASX:IMU) CEO RemunerationFeb 17
Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five YearsDec 24
|IMU||AU Biotechs||AU Market|
Return vs Industry: IMU underperformed the Australian Biotechs industry which returned -5% over the past year.
Return vs Market: IMU underperformed the Australian Market which returned -4.7% over the past year.
|IMU Average Weekly Movement||10.3%|
|Biotechs Industry Average Movement||8.8%|
|Market Average Movement||8.9%|
|10% most volatile stocks in AU Market||15.8%|
|10% least volatile stocks in AU Market||4.1%|
Stable Share Price: IMU is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: IMU's weekly volatility (10%) has been stable over the past year.
About the Company
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company’s HER-Vaxx is in Phase 1b/2 study for gastric cancer.
Imugene Limited Fundamentals Summary
|IMU fundamental statistics|
Is IMU overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IMU income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.0059|
|Net Profit Margin||-291.98%|
How did IMU perform over the long term?See historical performance and comparison